The encouraging results from dendritic cell-related cancer immunotherapy have created tremendous interest for its broad clinical application. Dendritic cells are the most potent antigen-presenting cells. In cancer patients, dendritic cell production and function along with other antitumor immune defenses are compromised. Autologous dendritic cells enriched and sensitized in vitro with tumor-associated antigens can effectively elicit host cellular immunity against cancer and result in clinical antitumor responses through either direct injection or ex vivo generation of antitumor T lymphocytes. In small group studies, clinical response rates have reached 50% in patients with advanced stage of cancer. These cellular products caused minimal side effects and were well tolerated. The isolation and preparation of clinical grade dendritic cells have been driven by transfusion medicine specialists who are well versed in similar processes for hematopoietic stem-cell preparation. The purpose of this article is to review the mechanisms of tumor immune surveillance and the biology of dendritic cells relevant to tumor antigen presentation, sensitization, and T-lymphocyte stimulation. Information on tumor-associated antigens and clinical trial results with dendritic cell-based cancer immunotherapy are summarized. The potential challenges for blood banking/transfusion medicine involving both technical and regulatory issues are discussed.

中文翻译：

---

基于树突细胞的免疫疗法用于癌症以及输血医学的相关挑战。

树突状细胞相关的癌症免疫疗法令人鼓舞的结果已经引起了广泛的临床应用兴趣。树突状细胞是最有效的抗原呈递细胞。在癌症患者中，树突状细胞的产生和功能以及其他抗肿瘤免疫防御功能受到损害。用肿瘤相关抗原在体外富集和敏化的自体树突状细胞可通过直接注射或离体产生抗肿瘤T淋巴细胞有效地引发宿主对癌症的细胞免疫力，并导致临床抗肿瘤反应。在小组研究中，晚期癌症患者的临床反应率已达到50％。这些细胞产物产生最小的副作用并且被很好地耐受。输血医学专家推动了临床级树突状细胞的分离和制备，他们深specialist造血干细胞制备的类似过程。本文的目的是综述肿瘤免疫监视的机制以及与肿瘤抗原呈递，致敏作用和T淋巴细胞刺激有关的树突状细胞的生物学特性。总结了有关肿瘤相关抗原的信息以及基于树突细胞的癌症免疫疗法的临床试验结果。讨论了涉及技术和法规问题的血库/输血医学的潜在挑战。本文的目的是综述肿瘤免疫监视的机制以及与肿瘤抗原呈递，致敏作用和T淋巴细胞刺激有关的树突状细胞的生物学特性。总结了有关肿瘤相关抗原的信息以及基于树突细胞的癌症免疫疗法的临床试验结果。讨论了涉及技术和法规问题的血库/输血医学的潜在挑战。本文的目的是综述肿瘤免疫监视的机制以及与肿瘤抗原呈递，致敏作用和T淋巴细胞刺激有关的树突状细胞的生物学特性。总结了有关肿瘤相关抗原的信息以及基于树突细胞的癌症免疫疗法的临床试验结果。讨论了涉及技术和法规问题的血库/输血医学的潜在挑战。